File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations

TitleMeta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations
Authors
KeywordsExome sequencing
Genome sequencing
Genomic diversity
Meta-analysis
Rare disease
Issue Date1-Sep-2023
PublisherAmerican College of Medical Genetics and Genomics
Citation
Genetics in Medicine, 2023, v. 25, n. 9 How to Cite?
Abstract

Purpose: This meta-analysis aims to compare the diagnostic and clinical utility of whole-exome sequencing (WES) versus whole-genome sequencing (WGS) in pediatric and adult patients with rare diseases across diverse populations.

Methods: A meta-analysis was conducted to identify studies from 2011-2021.

Results: One-hundred-and-sixty-one studies across 31 countries/regions were eligible, featuring 50,417 probands of diverse populations. Diagnostic rates of WES (0.38, 95% CI 0.36-0.40) and WGS (0.34, 95% CI 0.30-0.38) were similar (p=0.1). Within-cohort comparison illustrated a 1.2 times odds of diagnosis by WGS over WES (95% CI 0.79-1.83, p=0.38). WGS studies discovered a higher range of novel genes than WES studies, yet the rate of variant of unknown significance (VUS) did not differ (p=0.78). Among high-quality studies, clinical utility of WGS (0.77, 95% CI 0.64-0.90) was higher than WES (0.44, 95% CI 0.30-0.58) (p<0.01).

Conclusion: This meta-analysis provides an important update to demonstrate the similar diagnostic rates between WES and WGS and the higher clinical utility of WGS over WES. With the newly published recommendations for clinical interpretation of variants found in non-coding regions of the genome and the trend of decreasing VUS and WGS cost, it is expected that WGS will be more widely used in clinical settings.


Persistent Identifierhttp://hdl.handle.net/10722/328965
ISSN
2023 Impact Factor: 6.6
2023 SCImago Journal Rankings: 2.697
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChung, Claudia Ching Yan-
dc.contributor.authorHue, Shirley Pik Ying-
dc.contributor.authorNg, Nicole Ying Ting-
dc.contributor.authorDoong, Phoenix Hoi Lam-
dc.contributor.authorGenome Project Hong Kong,-
dc.contributor.authorChu, Annie Tsz Wai-
dc.contributor.authorChung, Brian Hon Yin-
dc.date.accessioned2023-08-05T07:54:16Z-
dc.date.available2023-08-05T07:54:16Z-
dc.date.issued2023-09-01-
dc.identifier.citationGenetics in Medicine, 2023, v. 25, n. 9-
dc.identifier.issn1098-3600-
dc.identifier.urihttp://hdl.handle.net/10722/328965-
dc.description.abstract<p><strong>Purpose: </strong>This meta-analysis aims to compare the diagnostic and clinical utility of whole-exome sequencing (WES) versus whole-genome sequencing (WGS) in pediatric and adult patients with rare diseases across diverse populations.</p><p><strong>Methods: </strong>A meta-analysis was conducted to identify studies from 2011-2021.</p><p><strong>Results: </strong>One-hundred-and-sixty-one studies across 31 countries/regions were eligible, featuring 50,417 probands of diverse populations. Diagnostic rates of WES (0.38, 95% CI 0.36-0.40) and WGS (0.34, 95% CI 0.30-0.38) were similar (p=0.1). Within-cohort comparison illustrated a 1.2 times odds of diagnosis by WGS over WES (95% CI 0.79-1.83, p=0.38). WGS studies discovered a higher range of novel genes than WES studies, yet the rate of variant of unknown significance (VUS) did not differ (p=0.78). Among high-quality studies, clinical utility of WGS (0.77, 95% CI 0.64-0.90) was higher than WES (0.44, 95% CI 0.30-0.58) (p<0.01).</p><p><strong>Conclusion: </strong>This meta-analysis provides an important update to demonstrate the similar diagnostic rates between WES and WGS and the higher clinical utility of WGS over WES. With the newly published recommendations for clinical interpretation of variants found in non-coding regions of the genome and the trend of decreasing VUS and WGS cost, it is expected that WGS will be more widely used in clinical settings.</p>-
dc.languageeng-
dc.publisherAmerican College of Medical Genetics and Genomics-
dc.relation.ispartofGenetics in Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectExome sequencing-
dc.subjectGenome sequencing-
dc.subjectGenomic diversity-
dc.subjectMeta-analysis-
dc.subjectRare disease-
dc.titleMeta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations-
dc.typeArticle-
dc.identifier.doi10.1016/j.gim.2023.100896-
dc.identifier.scopuseid_2-s2.0-85163186031-
dc.identifier.volume25-
dc.identifier.issue9-
dc.identifier.eissn1530-0366-
dc.identifier.isiWOS:001024722500001-
dc.identifier.issnl1098-3600-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats